69ɫ��Ƭ

Curious about 69ɫ��Ƭ’s global survey results? 

Read More

Aducanumab (Aduhelm^TM), a new drug designed to treat Alzheimer's disease was approved by the FDA on June 7, 2021. 69ɫ��Ƭ's Dr. Dave Rengachary discusses what this means for insurance, as well as the controversies around it.

Read More

Read More

Trey Reynolds, Executive Vice President, Strategy & New Business Development, MIB Group, Inc., presents on the jumbo solution and is joined by other leading voices in the fraud-fighting community at the 69ɫ��Ƭ Fraud Conference.

Read More

Today, a diagnosis of cancer requires a traditional biopsy consisting of direct tissue sampling and analysis, but liquid biopsies are changing the game. Read More

69ɫ��Ƭ's Hilary Henly provides an overview of natural and vaccine-induced COVID-19 immunity, how long immunity is likely to last, whether booster shots will be needed, and more.

Evidence to date suggests that individuals previously infected with SARS-CoV-2 who are... Read More

Multi-state models, or MSMs, can help actuaries better characterize individuals as they progress through disease states. 69ɫ��Ƭ's Kishan Bakrania, Chris Falkous, and Richard Russell provide a clear-eyed introduction to this form of modeling and share use cases...

Read More

69ɫ��Ƭ is a proud member of the , America’s only anti-fraud alliance speaking for consumers, insurance companies, government agencies, and others. We invit... Read More

As part of an ongoing series in On the Risk, 69ɫ��Ƭ's Taylor Pickett, an actuary, and Catie Muccigrosso, an underwriter, examine the relationship between their professions and underscore the crucial role underwriters play in the development and implementation o...

Read More

Up to 70% of breast cancer patients prescribed chemotherapy after their surgeries might not need it. But how can clinicians make that decision, and insurers determine whether to cover the determining tests?  Read More

Adjudication of overseas claims may be challenging, but being aware of red flags and having an effective claims strategy and processing framework will help ensure the validity of claims and avoid fraudulent activity. 
Read More

More than a year after a pandemic transformed the world of work, how are group disability insurers responding?  At 69ɫ��Ƭ’s 27th annual Disability Claim Leaders Forum, representatives from major carriers shared intriguing insights. 

Read More

Curious about 69ɫ��Ƭ's medical insights?  Contact us to learn m...

Read More

For 69ɫ��Ƭ's Curt Zepeda, underinsurance is an existential challenge for the insurance industry, and yet the digital tools are available to the group insurance sector to provide more personalized offers and help close the protection gap. He calls on the industry to ba... Read More

In 2020, 69ɫ��Ƭ produced a five-part series of articles exploring life insurance fraud in the time of COVID-19 as a lead-up to the 69ɫ��Ƭ Fraud Conference.  Read More

It's the million-dollar question: how should insurers respond to an emerging class of gene therapeutics that promise to cure or ease debilitating genetic disorders, rare diseases and cancers but can cost upwards of $1 million per treatment. Learn highlights from...

Read More

For insurers, the current puzzle is how to develop cost-effective products for mental health disorders with sufficient flexibility to cover a range of risks and maintain positive customer experiences, says 69ɫ��Ƭ's Dipali Jawalkar, Executive D...

Read More

Curious about 69ɫ��Ƭ’s Global Genetics Survey results? 

Read More

Brain fog ... blurred vision ... loss of taste ... these are just a few of the lingering, and sometimes debilitating, symptoms reported by COVID-19 long-haulers. Read More

Aligning Critical Illness definitions with clinical diagnoses is not an easy task, and the speed of medical advances can lead to difficulties applying CI definitions at claims stage. 69ɫ��Ƭ's Marilda Kotze and Anne Casey explore some of the common challenges that this c...

Read More